Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CGYO18021 / NRG-GY009 / Richard Moore

Research Question:
What are good and bad effects of adding atezolizumab to the usual chemotherapy (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab?

Basic Study Information

Purpose:
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02839707?term=GY009&rank=1
Study Reference #: CGYO18021

Lead Researcher (Principal Investigator)

Lead Researcher:  Richard Moore

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Return to Search